Table 2 Characteristics of new users of glucagon-like peptide-1 analogues
All Data Sources | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | Total | |
|---|---|---|---|---|---|---|---|---|---|
N | 587 | 753 | 1 158 | 2 035 | 1 160 | 950 | 714 | 7 357 | |
Women, % | 55.2 | 52.7 | 51.5 | 49.3 | 50.3 | 46.5 | 46.2 | 50.0 | |
Mean age | 57.9 | 58.2 | 58.7 | 58.0 | 57.6 | 58.6 | 57.2 | 58.1 | |
Age bands, % | 18-44 | 8.5 | 9.2 | 8.4 | 10.9 | 10.9 | 11.7 | 12.9 | 10.4 |
45-64 | 65.6 | 63.7 | 63.5 | 62.4 | 63.9 | 57.2 | 61.1 | 62.4 | |
65-84 | 25.9 | 26.8 | 28.0 | 26.1 | 24.8 | 29.3 | 25.9 | 26.7 | |
85+ | Â | 0.3 | 0.2 | 0.6 | 0.3 | 1.9 | 0.1 | 0.5 | |
Prior antidiabetic treatmentsa, % | No antidiabetics | 3.7 | 4.8 | 6.6 | 16.5 | 11.6 | 18.6 | 16.9 | 12.3 |
Insulin with/without non-insulin antidiabetics | 23.0 | 25.4 | 22.3 | 20.6 | 25.7 | 23.5 | 19.0 | 22.6 | |
Non-insulin antidiabetic monotherapy | 14.3 | 16.3 | 19.9 | 28.2 | 30.0 | 32.4 | 37.3 | 26.3 | |
≥1 non-insulin antidiabetic | 58.9 | 53.5 | 51.2 | 34.7 | 32.7 | 25.5 | 26.8 | 38.9 | |
Patients with 1 year follow-up, % | 99.8 | 99.7 | 99.9 | 99.7 | 99.3 | 98.9 | 0.0 | 89.9 | |
Patients with 1 year follow-up, N | 586 | 751 | 1 157 | 2 029 | 1 152 | 939 | - | 6 614 | |
Following antidiabetic treatmentsb, % | ≥1 additional dispensing of a GLP1a | 84.0 | 84.0 | 82.2 | 82.7 | 82.1 | 74.8 | - | 81.6 |
Persistent users of incretins (any) | 54.3 | 60.6 | 60.1 | 65.1 | 62.2 | 53.3 | - | 60.6 | |
Switchers to a DPP4i | 3.4 | 3.7 | 6.2 | 5.7 | 8.1 | 4.7 | - | 5.6 | |
≥1 additional dispensing of non-incretin antidiabetic | 91.6 | 91.1 | 86.3 | 86.1 | 84.7 | 79.9 | - | 86.1 | |
≥1 additional dispensing of any antidiabetic | 97.1 | 96.7 | 94.5 | 93.2 | 93.1 | 88.2 | - | 93.5 | |